AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating reissued by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Monday. They presently have a $23.00 target price on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 25.34% from the company’s current price.

The analysts wrote, “AMAG disclosed that the Makena auto-injector sNDA has been accepted for review and that the FDA set a PDUFA date of February 14, 2018.””

A number of other equities analysts also recently commented on the company. Barclays PLC reiterated an “equal weight” rating and set a $20.00 price objective (down previously from $25.00) on shares of AMAG Pharmaceuticals in a research report on Thursday, June 1st. ValuEngine downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. TheStreet downgraded AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 5th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $34.00 price objective (down previously from $40.00) on shares of AMAG Pharmaceuticals in a research report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. AMAG Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $29.44.

AMAG Pharmaceuticals (NASDAQ AMAG) traded down 2.45% during mid-day trading on Monday, reaching $17.90. The company had a trading volume of 421,079 shares. The stock has a 50 day moving average of $18.26 and a 200 day moving average of $23.88. The stock’s market capitalization is $627.31 million. AMAG Pharmaceuticals has a 52 week low of $16.00 and a 52 week high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a positive return on equity of 1.69% and a negative net margin of 5.61%. The company had revenue of $139.47 million for the quarter, compared to analysts’ expectations of $150.32 million. During the same quarter in the previous year, the business posted ($0.22) EPS. The business’s quarterly revenue was up 27.6% compared to the same quarter last year. Analysts anticipate that AMAG Pharmaceuticals will post $5.09 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “AMAG Pharmaceuticals, Inc. (AMAG) Earns Hold Rating from Cantor Fitzgerald” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/06/26/amag-pharmaceuticals-inc-amag-earns-hold-rating-from-cantor-fitzgerald.html.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 1,891 shares of AMAG Pharmaceuticals stock in a transaction on Monday, May 1st. The stock was sold at an average price of $24.45, for a total value of $46,234.95. Following the sale, the senior vice president now owns 36,777 shares in the company, valued at $899,197.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.80% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the stock. Skandinaviska Enskilda Banken AB publ increased its stake in AMAG Pharmaceuticals by 45.6% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 158,600 shares of the specialty pharmaceutical company’s stock worth $3,576,000 after buying an additional 49,700 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in AMAG Pharmaceuticals by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 607,980 shares of the specialty pharmaceutical company’s stock worth $13,710,000 after buying an additional 376,139 shares in the last quarter. Credit Suisse AG increased its stake in AMAG Pharmaceuticals by 122.3% in the first quarter. Credit Suisse AG now owns 145,442 shares of the specialty pharmaceutical company’s stock worth $3,280,000 after buying an additional 80,011 shares in the last quarter. Tudor Investment Corp ET AL increased its stake in AMAG Pharmaceuticals by 99.1% in the first quarter. Tudor Investment Corp ET AL now owns 22,300 shares of the specialty pharmaceutical company’s stock worth $503,000 after buying an additional 11,100 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in AMAG Pharmaceuticals during the first quarter worth approximately $403,000.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.